X4 PharmaceuticalsXFOR -2.44%29 Gross Margin % is 77.92% as of Mar. 2026, which is 2% above its 10-year median of 76.22. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 738 Biotechnology companies, X4 Pharmaceuticals ranks better than 74.12% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
X4 Pharmaceuticals had a gross margin of 77.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
X4 Pharmaceuticals Gross Margin % Related Terms
X4 Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for X4 Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XFOR vs ZURA, LYEL, LXEO: Gross Margin % Comparison
For the Biotechnology subindustry, X4 Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
X4 Pharmaceuticals (XFOR) has a Gross Margin % of 77.92% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on X4 Pharmaceuticals and its competitors. This is near median its historical median of 76.22. Over the past decade, X4 Pharmaceuticals' Gross Margin % has ranged from 68.83 to 83.60. According to the industry distribution chart, X4 Pharmaceuticals ranks #191 out of 738 companies in the Biotechnology industry, placing it in the top 25.9%.
Is X4 Pharmaceuticals' Gross Margin % too high?
X4 Pharmaceuticals' current Gross Margin % of 77.92% is near median its 10-year median of 76.22. Over the past 10 years, this metric has ranged from a low of 68.83 to a high of 83.60. The Biotechnology industry median Gross Margin % is 60.94. X4 Pharmaceuticals' value of 77.92% is 27.9% above this industry median. Based on the distribution chart, X4 Pharmaceuticals ranks #191 out of 738 companies in the Biotechnology industry, which is above the industry midpoint. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Gross Margin % compare to ZURA and LYEL?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #191 out of 738 companies for Gross Margin %. This puts X4 Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.94. X4 Pharmaceuticals' value of 77.92% is 27.9% above this benchmark. Historically, X4 Pharmaceuticals' own Gross Margin % has ranged from 68.83 to 83.60 over the past decade. While the company's 10-year median is 76.22 vs. the industry median of 60.94, X4 Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X4 Pharmaceuticals's current Gross Margin % of 77.92% is 27.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on X4 Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X4 Pharmaceuticals's current Gross Margin % is 77.92%, which is near median its own 10-year median of 76.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Gross Margin % of 77.92%. The current Gross Margin % is 77.92%, which is near median its 10-year median of 76.22 and 27.9% above the Biotechnology industry median of 60.94. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Gross Margin % is 77.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score
Get the complete analysis for XFOR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XFOR has been successfully added to your 
